ATE271130T1 - Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können - Google Patents
Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden könnenInfo
- Publication number
- ATE271130T1 ATE271130T1 AT98906268T AT98906268T ATE271130T1 AT E271130 T1 ATE271130 T1 AT E271130T1 AT 98906268 T AT98906268 T AT 98906268T AT 98906268 T AT98906268 T AT 98906268T AT E271130 T1 ATE271130 T1 AT E271130T1
- Authority
- AT
- Austria
- Prior art keywords
- substrates
- disclosed
- modified
- methods
- engineered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79752297A | 1997-02-07 | 1997-02-07 | |
US4672797P | 1997-05-16 | 1997-05-16 | |
PCT/US1998/002522 WO1998035048A2 (en) | 1997-02-07 | 1998-02-09 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE271130T1 true ATE271130T1 (de) | 2004-07-15 |
Family
ID=26724237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98906268T ATE271130T1 (de) | 1997-02-07 | 1998-02-09 | Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können |
Country Status (8)
Country | Link |
---|---|
US (5) | US6390821B1 (de) |
EP (1) | EP1017823B1 (de) |
JP (2) | JP3784076B2 (de) |
AT (1) | ATE271130T1 (de) |
AU (1) | AU755062B2 (de) |
CA (1) | CA2279846C (de) |
DE (1) | DE69825066T2 (de) |
WO (1) | WO1998035048A2 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU755062B2 (en) * | 1997-02-07 | 2002-12-05 | Princeton University | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
US6162613A (en) * | 1998-02-18 | 2000-12-19 | Vertex Pharmaceuticals, Inc. | Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases |
US7383135B1 (en) | 1998-05-04 | 2008-06-03 | Vertex Pharmaceuticals Incorporated | Methods of designing inhibitors for JNK kinases |
US6610483B1 (en) | 1999-07-23 | 2003-08-26 | Princeton University | Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof |
DE10024174A1 (de) * | 2000-05-17 | 2001-11-29 | Gsf Forschungszentrum Umwelt | Verfahren zum Selektieren von Inhibitoren für Enzyme |
US7792645B2 (en) * | 2000-08-30 | 2010-09-07 | The Salk Institute For Biological Studies | Three-dimensional structure of chalcone isomerase and methods of use thereof |
WO2002057418A2 (en) * | 2000-12-15 | 2002-07-25 | The Salk Institute For Biological Studies | Methods of producing polyketide synthase mutants and compositions and uses thereof |
AU2002259071A1 (en) | 2001-04-30 | 2002-11-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes |
US20060263800A1 (en) * | 2001-11-01 | 2006-11-23 | Princeton University | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
WO2003105723A2 (en) * | 2002-06-14 | 2003-12-24 | The Salk Institute For Biological Studies | Mutant plant caffeic acid/5-hydroxyferulic acid 3/5-0-methyltransferases (comt), methods for preparation and use thereof |
AU2003267145A1 (en) * | 2002-09-13 | 2004-04-30 | Irm, Llc | Highly specific modulators of gtpases for target validation |
US7425547B2 (en) * | 2002-09-30 | 2008-09-16 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
CA2535347A1 (en) * | 2003-08-15 | 2005-03-03 | Merck & Co., Inc. | 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists |
EA012220B1 (ru) * | 2004-10-19 | 2009-08-28 | Крка, Товарна Здравил, Д. Д., Ново Место | Твёрдая фармацевтическая композиция, содержащая донепезила гидрохлорид |
WO2006068760A2 (en) * | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
CA2626669A1 (en) * | 2005-10-13 | 2007-04-19 | Activesite Pharmaceuticals | Methods for indentification of inhibitors of enzyme activity |
KR20090017498A (ko) * | 2006-04-04 | 2009-02-18 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | Pi3 키나제 길항물질 |
WO2008095140A1 (en) * | 2007-01-31 | 2008-08-07 | Bids Trading, L.P. | Electronic block trading system and method of operation |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
SG10201605472WA (en) | 2008-01-04 | 2016-09-29 | Intellikine Llc | Certain Chemical Entities, Compositions And Methods |
US8065217B2 (en) * | 2008-02-12 | 2011-11-22 | Bids Trading, L.P. | Real-time portfolio balancing and/or optimization system and method |
WO2009114874A2 (en) * | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
KR20110039326A (ko) | 2008-07-08 | 2011-04-15 | 인텔리카인, 인크. | 키나제 억제제 및 사용 방법 |
US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
EP2346508B1 (de) | 2008-09-26 | 2016-08-24 | Intellikine, LLC | Heterocyclische kinasehemmer |
WO2010045542A2 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
EP2427195B1 (de) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclische verbindungen und ihre verwendung |
CA2771532C (en) | 2009-08-17 | 2021-03-23 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
AR084824A1 (es) | 2011-01-10 | 2013-06-26 | Intellikine Inc | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas |
CN103491962B (zh) | 2011-02-23 | 2016-10-12 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
KR20150061651A (ko) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ire1의 조절 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
EP2976086B1 (de) | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Kombination aus katalytischen mtorc 1/2-inhibitoren und selektiven inhibitoren der aurora-a-kinase |
US10769725B1 (en) | 2013-06-05 | 2020-09-08 | Bids Trading, L.P. | System and methods for optimizing the effectiveness of interaction between participants in an electronic trading environment |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MY175778A (en) | 2013-10-04 | 2020-07-08 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
SG11201607705XA (en) | 2014-03-19 | 2016-10-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6980649B2 (ja) | 2015-09-14 | 2021-12-15 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法 |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3474856B1 (de) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Kombinationstherapie |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
CA2054602C (en) | 1991-10-31 | 2003-04-22 | Anthony Pawson | Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system |
US5443962A (en) | 1993-06-04 | 1995-08-22 | Mitotix, Inc. | Methods of identifying inhibitors of cdc25 phosphatase |
US5620676A (en) * | 1994-03-08 | 1997-04-15 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically active ATP analogs |
US5731343A (en) | 1995-02-24 | 1998-03-24 | The Scripps Research Institute | Method of use of radicicol for treatment of immunopathological disorders |
US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
US5914393A (en) * | 1995-12-05 | 1999-06-22 | Incyte Pharmaceuticals, Inc. | Human Jak2 kinase |
EP0929553B1 (de) | 1996-10-02 | 2005-03-16 | Novartis AG | Pyrimiderivate und verfahren zu ihrer herstellung |
AU755062B2 (en) | 1997-02-07 | 2002-12-05 | Princeton University | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
US6162613A (en) | 1998-02-18 | 2000-12-19 | Vertex Pharmaceuticals, Inc. | Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases |
US5965352A (en) | 1998-05-08 | 1999-10-12 | Rosetta Inpharmatics, Inc. | Methods for identifying pathways of drug action |
ES2206191T3 (es) | 1999-01-11 | 2004-05-16 | Princeton University | Inhibidores de alta afinidad para validacion de dianas y usos de los mismos. |
US6610483B1 (en) | 1999-07-23 | 2003-08-26 | Princeton University | Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof |
-
1998
- 1998-02-09 AU AU61535/98A patent/AU755062B2/en not_active Ceased
- 1998-02-09 JP JP53499998A patent/JP3784076B2/ja not_active Expired - Fee Related
- 1998-02-09 WO PCT/US1998/002522 patent/WO1998035048A2/en active IP Right Grant
- 1998-02-09 AT AT98906268T patent/ATE271130T1/de not_active IP Right Cessation
- 1998-02-09 CA CA002279846A patent/CA2279846C/en not_active Expired - Fee Related
- 1998-02-09 EP EP98906268A patent/EP1017823B1/de not_active Expired - Lifetime
- 1998-02-09 US US09/367,065 patent/US6390821B1/en not_active Expired - Lifetime
- 1998-02-09 DE DE69825066T patent/DE69825066T2/de not_active Expired - Lifetime
-
2000
- 2000-05-10 US US09/568,466 patent/US6521417B1/en not_active Expired - Fee Related
-
2001
- 2001-01-03 US US09/752,723 patent/US20020016976A1/en not_active Abandoned
- 2001-11-01 US US09/985,061 patent/US7026461B1/en not_active Expired - Fee Related
- 2001-11-01 US US09/985,157 patent/US7049116B2/en not_active Expired - Fee Related
-
2004
- 2004-03-24 JP JP2004087151A patent/JP2004248675A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1017823B1 (de) | 2004-07-14 |
US7026461B1 (en) | 2006-04-11 |
CA2279846A1 (en) | 1998-08-13 |
US7049116B2 (en) | 2006-05-23 |
DE69825066T2 (de) | 2005-08-25 |
DE69825066D1 (de) | 2004-08-19 |
JP2002503953A (ja) | 2002-02-05 |
AU755062B2 (en) | 2002-12-05 |
JP3784076B2 (ja) | 2006-06-07 |
MX9907317A (es) | 2002-09-02 |
CA2279846C (en) | 2008-06-03 |
AU6153598A (en) | 1998-08-26 |
US6390821B1 (en) | 2002-05-21 |
US20020146797A1 (en) | 2002-10-10 |
US6521417B1 (en) | 2003-02-18 |
JP2004248675A (ja) | 2004-09-09 |
US20020016976A1 (en) | 2002-02-07 |
EP1017823A2 (de) | 2000-07-12 |
WO1998035048A2 (en) | 1998-08-13 |
WO1998035048A3 (en) | 1999-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE271130T1 (de) | Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können | |
DE69731226D1 (de) | Verwendung von substrat-subtraktionsbibliotheken zur unterscheidung von enzymspezifitäten | |
ATE316147T1 (de) | Enzymsensor | |
ATE248170T1 (de) | Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung | |
IL170669A0 (en) | Anaplastic lymphoma kinase assay, reagents and compositions thereof | |
AU1929199A (en) | Methods for the recovery and measurement of troponin complexes | |
ATE419392T1 (de) | Verfahren zum nachweis von alkyliertem cytosin in dna | |
DE69739898D1 (de) | Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten | |
ATE445158T1 (de) | Toxizitätstypisierung unter verwendung von leberstammzellen | |
WO2002047535A3 (en) | High throughput assay to detect inhibitors of the map kinase pathway | |
WO2001007088A3 (en) | Methods for treating therapy-resistant tumors | |
ATE238551T1 (de) | Homogene nachweisverfahren zur bestimmung der phosphorylierungsaktivitäten von biologischem material | |
ATE540966T1 (de) | Von phenoxazinon abgeleitete neue enzymsubstrate und deren verwendung als entwickler bei der detektion von mikroorganismen mit peptidaseaktivität | |
ATE288922T1 (de) | Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen | |
GB9710154D0 (en) | Detection of retroviruses | |
DK1095032T3 (da) | Hidtil ukendte fluorescerende CYP2D-assayreagenser | |
ATE440964T1 (de) | Verfahren zur detektion von polynukleotidkinase und deren verwendung als markierung | |
BG108513A (en) | METHOD FOR SCINTILLATION IDENTIFICATION OF AMINOGLYCOZIDE-BINDING MOLECULES (ABMs) | |
FR2779430B1 (fr) | Dithio-bis-nitrobenzenes substitues et leurs applications | |
DE60113660D1 (de) | G-protein gekoppelter rezeptor | |
WO2002010439A3 (en) | Macromolecular enzyme substrates | |
WO2002018604A3 (en) | Methods and compositions for determining isomerase enzymatic activity | |
EP1309707A4 (de) | Testverfahren zur bestimmung der alterativen verlangerung von telomeren | |
ATE128236T1 (de) | Verwendung von atelokollagen als festträger für die fixierung eines spezifischen fängers. | |
ES2143934A1 (es) | Cuantificacion amperometrica y voltamperometrica de azul de indigo para la determinacion de hidrolasas y desarrollo de biosensores. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |